the advent of bispecific antibodies for multiple myeloma
Published 1 year ago • 104 plays • Length 1:45Download video MP4
Download video MP3
Similar videos
-
6:35
the benefits of bispecific antibodies for treating multiple myeloma
-
1:45
using the available repertoire of bispecific antibodies for treating multiple myeloma
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
7:05
developments in the use of bispecific antibodies in myeloma and challenges in this space
-
3:37
bispecific antibodies in multiple myeloma: their current role and the future
-
4:04
the future of myeloma treatment and the possibility of cure
-
6:09
bispecific antibodies | high impact topic (hit)
-
4:47
efficacy of novel t-cell bispecific engaging antibody, cd20-tcb (rg6026), for r/r nhl
-
1:20
a comparison of bispecific antibodies emerging in multiple myeloma
-
2:45
emerging treatments for myeloma: quadruplets, bispecific antibodies & car t-cells
-
1:15
safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
-
2:22
outcomes and management of patients with r/r myeloma who progress on bispecific antibodies
-
2:55
bispecific antibodies for myeloma: highlights from ash 2020
-
1:17
the promise of bispecific antibodies in the treatment of nhl
-
4:26
antibodies in multiple myeloma and their impact on treatment
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
2:56
the exciting future of bispecific antibodies
-
1:23
investigating bispecific antibodies in high-risk smoldering myeloma: the immunoprism platform study
-
6:13
phase i study of forimtamig, a gprc5dxcd3 bispecific antibody, in r/r multiple myeloma
-
1:47
immunoprism: a platform study investigating bispecific antibodies in smoldering multiple myeloma
-
2:44
dual-targeting bispecific antibody alnuctamab in r/r multiple myeloma